Aytu Posts Q1 FY2027 Revenue of $14.8M, Skips Earnings Call Ahead of $2.70/Share Rosemont Deal
AYTU is trading near its 52-week low of $1.75 (4.0% above the low).
Summary
Aytu reported Q1 FY2027 revenue of $14.8M, up 6.9%, with EXXUA at $4.9M and a ($3.9)M net loss, and skipped its earnings call due to the pending $2.70-per-share Rosemont merger.
Key Events · Earnings and Guidance · AYTU
-
Q1 FY2027 Revenue Up 6.9%
Net revenue was $14.8 million versus $13.9 million a year earlier, with gross profit of $9.4 million, or 63.6% of revenue.
-
EXXUA Growth Offsets ADHD Decline
EXXUA net revenue reached $4.9 million, up 24.5% from $3.9 million in Q4 FY2026, on 4,400 prescriptions (+32.5% sequentially), while the ADHD portfolio fell to $7.7 million from $13.2 million on generic competition for Adzenys XR-ODT.
-
Net Loss Widens to ($3.9)M
Net loss was ($3.9) million, or ($0.20) per share, versus net income of $2.0 million a year earlier; Adjusted EBITDA was ($2.6) million versus ($0.6) million.
-
Cash Slips to $25.5M
Cash and cash equivalents were $25.5 million at September 30, 2026, down from $26.3 million at June 30, 2026, with $0.3 million used in operating activities.
Analysis · AYTU · Life Sciences
With the merger terms already public, the fresh information here is the quarterly numbers. Revenue rose 6.9% to $14.8M, but the mix shifted sharply: EXXUA grew 24.5% sequentially to $4.9M while the ADHD portfolio fell to $7.7M from $13.2M as promotional spend moved to EXXUA and generics hit Adzenys XR-ODT. The bottom line swung to a ($3.9)M net loss from $2.0M of income a year ago, and Adjusted EBITDA worsened to ($2.6)M from ($0.6)M. Against a $2.70 all-cash tender offer, the $25.5M of cash means operating results matter less to the share price than deal completion, but they show the EXXUA ramp that underpins the $56M fully-diluted valuation. The company also canceled its earnings call because of the pending merger.
How filings like this one have moved
In the 30 days to Nov 15, 2026, 37.5% of the 3713 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was 0.00%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, AYTU was trading at $1.82 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $19.8M. The 52-week trading range was $1.75 to $3.07. This filing was assessed with neutral market sentiment and an importance score of 7 out of 10.